BAM
CALA

Bruderman Asset Management’s Calithera Biosciences, Inc CALA Stock Holding History

Bruderman Asset Management’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-100
Closed -$13K – 624
2019
Q1 		$13K Hold
100
– – ﹤0.01% 418
2018
Q4 		$8K Buy
+100
New +$9.86K ﹤0.01% 457

Other funds holding CALA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bruderman Asset Management's CALA Position: Q2 2019 in Review

Bruderman Asset Management sold out of Calithera Biosciences, Inc (CALA) in Q2 2019, closing a stake of 100 shares — an estimated $13K sold.

Bruderman Asset Management first reported a position in CALA in Q4 2018 and held it in 2 quarters. The position peaked at $13K in Q1 2019. 92 funds tracked by Wall St. Rank hold CALA as of Q2 2019.

  • Bruderman Asset Management reported no remaining Calithera Biosciences, Inc position as of Q2 2019 after selling out during the quarter.
  • Bruderman Asset Management sold 100 Calithera Biosciences, Inc shares in Q2 2019, an estimated $13K.
  • Bruderman Asset Management first reported a position in Calithera Biosciences, Inc in Q4 2018 and held it in 2 quarters.
  • Bruderman Asset Management's Calithera Biosciences, Inc position peaked at $13K in Q1 2019.
  • 92 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q2 2019.

Based on Bruderman Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.